Activity Overview
This Expert Illustrations and CommentariesTM is a
video-based program in which 2
experts discuss the management of neovascular retinal disease with the
use of newer anti-VEGF agents. Their
discussion is enriched by
video animation illustrating the mechanism of action of these therapies
and the factors that guide
the determination of treatment intervals. This unique format is designed to
help clinicians identify best practices in the management of neovascular age-related macular
degeneration (nAMD), diabetic
macular edema (DME), and retinal vein occlusion (RVO), and to improve outcomes for their
patients with these diseases.
Target Audience
This activity is directed toward retina specialists, comprehensive ophthalmologists, and other eye care professionals involved in the treatment of neovascular retinal disease, including nAMD, DME, and RVO.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the pharmacologic basis for the extended durability of anti-VEGF agents, including the relationship between molar concentration, receptor occupancy, and dosing interval
- Interpret pivotal clinical trial extension data to evaluate how patients progress through individualized treat-and-extend regimens across nAMD, DME, and RVO
- Apply a structured, evidence-based framework for treatment selection and switching decisions in the current anti-VEGF landscape
Talia Kaden, MD
Assistant Professor of Ophthalmology
New York, NY
Disclosures: Talia Kaden, MD has no relevant financial relationships with ineligible companies.
Diana Do, MD
Professor of Ophthalmology and Vice Chair for Clinical Affairs
Byers Eye Institute
Stanford University
Clinic Chief of Ophthalmology
Stanford, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Apellis Pharmaceuticals, LumiThera, Neurotech Pharmaceuticals. Grant/Research Funding: Apellis Pharmaceuticals, LumiThera, Neurotech Pharmaceuticals.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity
was planned in accordance with the ACCME Standards for Integrity and
Independence to ensure balance, objectivity, independence, and scientific
rigor. Faculty were instructed to use generic names when possible and to base
recommendations on the best available evidence. Proprietary product names may
be referenced in clinical discussion for educational purposes only and do not
imply endorsement.
This activity may include discussion of
investigational, unapproved, or off‑label uses of
drugs or devices. Learners are advised to consult prescribing information for
products discussed. Content is provided for educational purposes only and is
not a substitute for the independent clinical judgment of a health care
professional. Learners are encouraged to critically evaluate the information
presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools
to support educational development. All content was reviewed and approved by
qualified faculty or planners. The accredited provider retains full
responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
